BioWorld

May 13, 2003

View Archived Issues

HGS Gains Exclusive License From Abgenix For CCR5 MAb

Human Genome Sciences Inc. exclusively licensed rights from Abgenix Inc. to develop a fully human monoclonal antibody to the CCR5 receptor, for which Abgenix earns an undisclosed milestone payment. (BioWorld Today) Read More

Genentech, XOMA Stop Trial In RA Because Of Lack Of Efficacy

Read More

Epimmune Enters Agreement For $13.5M Stock Merger With Anosys

Read More

Blue Heron Making Waves With Products For Gene Synthesis

Read More

BIO Asks Congress To Revisit Rule On Reimbursement Rates

Read More

Other News To Note

Read More

Appointments And Advancements

Read More